Relfovetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor |
| Clinical data | |
| Other names | ZTS-00084768 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C6580H10118N1760O2038S46 |
| Molar mass | 147964.37 g·mol−1 |
Relfovetmab is an experimental veterinary medication. It is a felinized monoclonal antibody targeting nerve growth factor. Nerve growth factor binds to TrkA receptors located on immune cells to elicit the release of additional proinflammatory mediators, including nerve growth factor itself.[1] These inflammatory mediators lead to further peripheral sensitization involved in pain perception.[1] The inhibition of nerve growth factor was demonstrated to provide relief from pain associated with osteoarthritis.[1]
Society and culture
[edit]Legal status
[edit]In September 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Portela, solution for injection, intended for cats.[1] The applicant for this veterinary medicinal product is Zoetis Belgium.[1]
Names
[edit]Relfovetmab is the international nonproprietary name.[2]
References
[edit]- ^ a b c d e "Portela EPAR". European Medicines Agency (EMA). 12 September 2025. Retrieved 28 September 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
External links
[edit]- "Relfovetmab ( Code - C174722 )". EVS Explore. Retrieved 28 September 2025.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |